TABLE 1.

Pharmacotherapy agents and behavioral treatment for alcohol use disorders specifically considering gender differences.

Treatment	Recommendation	Use in advanced liver disease	Hepatotoxicity	Special consideration/barriers based on gender
Behavioral therapy (i.e., cognitive; motivational enhancement)	First line	Yes	NA	Consider for women: ‐Cultural stigma; fear of losing childcare ‐Depression more than anxiety ‐Mental disease ‐Lower income
Naltrexone	First line	Avoid in Child‐Pugh class C	Possible	‐No difference in efficacy in both sex ‐Higher rate of discontinuation in women possibly due to side effects
Acamprosate	Second line	Yes	Not reported	‐No difference on any measure of efficacy, safety, or tolerability in both sex ‐Some small experience in pregnant women did not show poor maternal or neonatal health outcomes
Baclofen	NA	Yes	Not reported	‐Women my benefit from lower dose than men
Gabapentin	Second line	Yes	Not reported	‐No data available, apparently no difference. However, the trials available included men more than women
Topiramate	Second line	Avoid in patients with hepatic encephalopathy	Not reported	‐No data available, apparently no difference. However, data on smoking cessation on topiramate favors men than women